Oncology Corporate Profile
| 3.8000 | |
| 0.0000 |
Fortress Biotech, Inc. is a biopharmaceutical company dedicated to acquiring, developing and commercializing novel pharmaceutical and biotechnology products. Fortress plans to develop and commercialize products that it acquires both directly as well as indirectly by establishing subsidiary companies, also known as Fortress Companies. The Company will leverage its biopharmaceutical business expertise and drug development capabilities to help the Fortress Companies achieve their goals.
Website: http://www.fortressbiotech.com
| Brand / Product | Class | Area of Study | Phase | Partnership |
|---|---|---|---|---|
| CD123 CAR | CAR T-cell therapy | Acute Myelogenous Leukemia (AML) | I | Mustang Bio |
| CNDO-109 | CAR T-cell therapy | Acute Myelogenous Leukemia (AML) | I | Fortress Biotech |
| IL13Ra2-specific CAR | CAR T-cell therapy | Glioma | I | Mustang Bio |
| CK-101 | EGFR inhibitor | Non Small Cell Lung Cancer (NSCLC) | I | Checkpoint Theraputics |
| CK-102 | PARP inhibitor | Various cancer types | I | Checkpoint Theraputics |
View additional information on product candidates here »
3/30/2017 12:00 pm
[GlobeNewswire] - NEW YORK, March 30, 2017-- Fortress Biotech, Inc., a biopharmaceutical company dedicated to acquiring, developing and commercializing novel pharmaceutical and biotechnology products, today announced that ...
3/30/2017 12:03 am
3/23/2017 05:00 pm
3/22/2017 10:05 am
